IRVING, Texas, USA, March 31, 2026
Caris Life Sciences has announced final results from the Achieve 1 study, demonstrating high sensitivity and specificity of its Caris Detect™ multi-cancer early detection (MCED) test, marking a major advancement in precision oncology diagnostics and early cancer screening technologies. The study confirms that whole genome sequencing-based detection significantly outperforms traditional methylation-based approaches, reinforcing the test’s potential to transform early cancer diagnosis and clinical decision-making.
High Sensitivity and Specificity Across Cancer Stages
The Achieve 1 study enrolled 3,014 participants across high-risk and symptomatic populations, providing a comprehensive evaluation of Caris Detect’s diagnostic performance. The results demonstrated strong sensitivity across cancer stages, including 56.8% for Stage I, 67.7% for Stage II, 98.6% for Stage III, and 79.0% for Stage IV cancers, highlighting the test’s ability to detect cancers even at early stages.
Importantly, the test achieved exceptionally high specificity, with 99.2% in asymptomatic individuals and 96.0% in high-risk or benign populations, minimizing false positives and improving diagnostic confidence. The combined sensitivity for early-stage cancers (Stage I and II) reached 60.3%, a critical benchmark for effective early detection strategies.
These results underscore the importance of multi-dimensional genomic analysis, as Caris Detect leverages a vast dataset of over 50 billion molecular markers derived from more than 1 million cases, enabling highly accurate detection of cancer-related biological signals.
Advertisement
Whole Genome Sequencing Enhances Diagnostic Accuracy
Caris Detect utilizes whole genome sequencing (WGS) combined with advanced artificial intelligence (AI) models to identify complex molecular signatures associated with cancer. This approach provides greater resolution and sensitivity compared to single-modality diagnostic methods, allowing for the detection of subtle genomic alterations that may be missed by conventional techniques.
The study findings demonstrate that WGS-based diagnostics can capture diverse molecular changes across multiple cancer types, including breast, lung, prostate, and colorectal cancers. This capability positions Caris Detect as a next-generation diagnostic platform capable of supporting multi-cancer screening through a single blood test, significantly improving clinical workflow efficiency and patient experience.
Furthermore, the integration of AI-driven analytics enables continuous improvement of diagnostic accuracy, with future plans to incorporate additional data layers such as whole transcriptome sequencing, further enhancing the test’s performance and clinical utility.
Clinical Impact and Future Development Pathway
The strong performance of Caris Detect has significant implications for early cancer detection and precision medicine, as earlier diagnosis is closely associated with improved survival rates and treatment outcomes. By enabling detection at lower disease burden and earlier stages, the test has the potential to shift clinical practice toward preventive oncology and proactive patient management.
Caris Life Sciences aims to expand the platform by integrating multiple biological “pillars,” including genomic, transcriptomic, and clinical data, to create a comprehensive diagnostic ecosystem. This approach supports not only early detection but also treatment selection, disease monitoring, and drug development applications.
As the company advances toward commercialization, ongoing validation studies and regulatory engagement will be critical to ensuring clinical adoption and global market acceptance. The scalability of the platform, supported by advanced computing infrastructure and large-scale data analytics, positions Caris Detect as a key innovation in the future of oncology diagnostics.
A Breakthrough in Multi-Cancer Early Detection
The finalized Achieve 1 study results establish Caris Detect as a highly accurate and scalable multi-cancer early detection solution, with the potential to redefine how cancers are detected, diagnosed, and managed. By combining whole genome sequencing with AI-driven analytics, Caris is advancing the field of precision oncology, offering a powerful tool to improve early diagnosis and ultimately enhance patient outcomes worldwide.
Source: Caris Life Sciences press release
